Journal
CURRENT OPINION IN IMMUNOLOGY
Volume 64, Issue -, Pages 80-87Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2020.03.004
Keywords
-
Categories
Funding
- NCI NIH HHS [P01 CA217805] Funding Source: Medline
Ask authors/readers for more resources
Immune-targeted approaches are rapidly changing the therapeutic landscape for cancer. In spite of that, most patients show resistance or acquire resistance to these therapies. Increasing work describing the tumor microenvironment (TME) has highlighted this space as one of the key determinants in tumor immune response and immunotherapeutic success. Frequently overlooked within this space, cancer-associated fibroblasts (CAFs) within the TME have surfaced as an important dictator of the tumor immune response. Herein, we review recent advances in defining the role of CAF-immune cell interactions in solid tumors and prospects for targeting stroma to overcome resistance to immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available